Akeso
Native name | 康方生物科技(開曼)有限公司 |
|---|---|
| Company type | Public |
| SEHK: 9926 | |
| Industry | Biopharmaceutical |
| Founded | 19 March 2012 |
| Founders |
|
| Headquarters | Zhongshan, Guangdong, China |
Key people | Michelle Xia (Chairwoman & CEO) |
| Revenue | CN¥2.04 billion (2024) |
| CN¥−501.09 million (2024) | |
| Total assets | CN¥12.76 billion (2024) |
| Total equity | CN¥6.75 billion (2024) |
Number of employees | 3,035 (2024) |
| Website | www |
| Footnotes / references | |
Akeso, Inc (Akeso; Chinese: 康方生物; pinyin: Kāngfāng Shēngwù) is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong.
It is best known for developing Ivonescimab, a cancer treatment antibody.